Antengene (6996 HK)

Analysis

Health Care • China

Antengene is a global, R&D-driven, commercial-stage biotech company focused on discovering, developing, manufacturing, and commercializing first-in-class/best-in-class therapeutics for hematologic malignancies and solid tumors. Its pipeline includes in-house discovered programs like ATG-022 and ATG-101, and its lead commercial asset is XPOVIO® (selinexor). The company also developed the AnTenGager® T cell engager platform. Antengene is headquartered in Shanghai, China, and was founded in 2017.

Refresh

Exchange Announcement • 14 Oct 2026 17:30

Next Day Disclosure Return

Exchange Announcement • 13 Oct 2026 17:34

Next Day Disclosure Return

Exchange Announcement • 12 Oct 2026 17:46

Next Day Disclosure Return

Exchange Announcement • 09 Oct 2026 17:37

Next Day Disclosure Return

Exchange Announcement • 08 Oct 2026 18:03

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00